All Articles

Ibrutinib, a B-cell receptor pathway inhibitor, is approved in the United States for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and allows for treatment without chemotherapy.

Chimeric antigen receptor (CAR) T cells are engineered from a patient’s own immune cells to redirect them to attack tumor cells.

Breast cancer occurs predominantly in older, postmenopausal women (>50 years), although the incidence of ABC in younger, premenopausal women is increasing.

To honor our connection to the field of breast cancer, we dedicate a special annual edition of JONS to breast cancer and the strides being made in the treatment of this disease as part of our Best Practices series.

A breast cancer diagnosis can be difficult for women of any age, but young women can have unique needs that make this experience more complex.

A breast nurse navigator can perform patient-centered education on breast cancer type and possible treatment options using the inclusive pathology report, as well as be available during the disease trajectory to proactively guide the patient with additional education and support.

Intercepting, translating, consoling, advocating, and smoothing the rocky road for breast cancer patients, nurse navigators are the linchpins for cancer patients from diagnosis through treatment. These are some of the nurse navigators whom patients encounter on their journey.

Scalp cooling devices that allow patients treated with chemotherapy to retain their hair are used more commonly in Europe than in the United States, but this may be about to change now that the FDA has approved 2 scalp cooling devices: the DigniCap (approved in 2015) and the Paxman scalp cooling device (approved in 2017).

On behalf of the Academy of Oncology Nurse & Patient Navigators (AONN+) leadership council and the conference faculty, I invite you to invest in your navigation career by attending the conference designed especially for you.

The authors present findings from their study aiming to examine the associations between the Independent Specialty Medical Advocate model of patient navigation and intermediate patient health outcomes in newly diagnosed patients.